Skip to main content

October 2022, Vol 12, No 10

Decades ago, I remember when biosimilars were a light on the horizon. Visions of sharply discounted alternatives to reference brands that could swoop in and help patients receive the care they needed at prices that were at least 50% below current market rates. Read More ›

Digital health technologies have the potential to help transform patient care, but there are barriers that need to be overcome, said Deb Schrag, MD, MPH, George J. Bosl Chair, Department of Medicine, Memorial Sloan Kettering Cancer Center (MSKCC), and Professor, Medicine, Weill Cornell Medical College, New York City, during a keynote lecture at the European Society for Medical Oncology Congress 2022. Read More ›

With cyberattacks on health systems and medical practices omnipresent in the headlines, it can be tempting for overextended administrators and executives to reach a point in which the gravity of the situation feels overwhelming. The never-ending onslaught of breaches, malware attacks, ransomware, and data theft has left many administrators numb. Read More ›

For the first time, a novel gamma secretase inhibitor has shown extremely promising results in desmoid tumors—a rare, benign, but potentially aggressive tumor type. Read More ›

Although it is well established that air pollution is associated with lung cancer, how this occurs has not been well described. Read More ›

Minimizing some of the most distressing symptoms of cancer and its treatment requires systematic screening and risk assessment, as well as a focus on the underlying cause of these symptoms, according to experts at the European Society for Medical Oncology (ESMO) Congress 2022. Read More ›

A survey of US physicians who prescribe biologics to their patients revealed that 92% were confident in the safety and efficacy of biosimilars, 89% would prescribe a biosimilar to a new patient, and 80% were comfortable initiating the switching of patients who are stable on their current biologic medication to a biosimilar. Read More ›

Several baseline factors were associated with an increased risk for treatment discontinuation in the phase 3 monarchE clinical trial, which assessed adjuvant abemaciclib (Verzenio) in patients with hormone receptor–positive, HER2-negative early breast cancer, according to findings from a multivariate analysis presented during the American Society of Clinical Oncology Annual Meeting. Read More ›

FDA-approved oral cancer drugs are not cheap, and many patients are unable to afford these promising therapies with extremely high price tags. Read More ›

The following clinical trials represent a selection of key studies currently recruiting patients with breast cancer for inclusion in investigations of new therapies and new regimens of existing treatments for the disease. Read More ›